26 / 42
• Response: 33 – 68%
• PFS: 5.5 – 8.4 m
• OS / 1 year OS: 11.6 – 19.2 m / 50 – 86%
• Grade 3/4 AEs: 25 – 72%
• No Impact of PD-L1 Expression
Rizvi N et al, J Clin Oncol 2016;
Liu S et al, ASCO 2017; abstract
Phase I
Nivolumab + CT,
Atezolizumab + CT